Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
AssigneeNanopharmaceuticals LLC
InventorsPaul J. Davis, Shaker A. Mousa
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.
Claims27
A method for inducing radiosensitivity in normal cancer cells or radioresistant cancer cells comprising the steps of:
- providing cancer cells having at least one of normal cancer cells and radioresistant cancer cells;
- conjugating an anti-angiogenic thyroid hormone analog to a polymer via a linker;
- formulating the anti-angiogenic thyroid hormone analog into a nanoparticle;
- administering an effective amount of an anti-angiogenic thyroid hormone analog to a patient, wherein the anti-angiogenic thyroid hormone analog is selected from the group consisting of tetraiodothyroacetic acid (Tetrac), triiodothyroacetic acid (Triac), monoclonial antibody LM609, XT199 and combinations thereof, wherein the anti-angiogenic thyroid hormone analog acts exclusively at the cell surface receptor αVβ3;
- and
- irradiating the cancer cells with an external radiation source.
A method for inducing radiosensitivity in normal cancer cells or radioresistant cancer cells in a patient comprising the steps of:
- conjugating an anti-angiogenic thyroid hormone analog to a polymer via a linker;
- formulating the anti-angiogenic thyroid hormone analog into a nanoparticle;
- administering an effective amount of the anti-angiogenic thyroid hormone analog to the patient wherein said anti-angiogenic thyroid hormone analog is selected from the group consisting of tetraiodothyroacetic acid (Tetrac), triiodothyroacetic acid (Triac), monoclonial antibody LM609, XT199 and combinations thereof, wherein said thyroid hormone analog binds exclusively to the cell surface receptor for thyroid hormone on integrin αvβ3 at the cell membrane level;
- and
- exposing the patient to an external radiation source.
Dependencies are inferred from the claim text.